What is Elite Pharmaceuticals Inc's earnings per share (EPS)?

Elite Pharmaceuticals Inc (ELTP) reported diluted earnings per share of $0.03 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Elite Pharmaceuticals Inc Financials

ELTP

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Elite Pharmaceuticals Inc (ELTP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ELTP FY2025 2026-06-29

Rapid revenue scaling is now dropping into operating profit and cash flow, even while reported earnings were distorted below the line.

Net margin moved from 35.5% in FY2024 to -5.1% in FY2025, but that reversal does not match the operating picture. Operating cash flow simultaneously swung from -$3.2M to $7.5M, and operating margin also improved, pointing to a below-the-line distortion rather than weaker core selling economics.

The clearest operating pattern is fixed-cost absorption: revenue rose from $34.2M in FY2023 to $84.0M in FY2025 while gross margin stayed near the high-40s, so more of each new sales dollar reached operating income. Elite also kept reinvesting in development, which makes the margin lift more meaningful because it was not achieved simply by cutting back on operating spend.

Total liabilities climbed from $26.1M to $42.9M between FY2024 and FY2025, so expansion is being financed with more obligations than before. But because short-term liquidity strengthened and free cash flow turned positive, the added balance-sheet burden does not look like an immediate cash squeeze.

Financial Health Signals

Financial Profile 82/100

Based on FY2026 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Elite Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Elite Pharmaceuticals Inc has an operating margin of 33.0%, meaning the company retains $33 of operating profit per $100 of revenue. This strong profitability earns a score of 83/100, reflecting efficient cost management and pricing power. This is up from 23.3% the prior year.

Growth

100

Elite Pharmaceuticals Inc's revenue surged 77.1% year-over-year to $148.9M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Elite Pharmaceuticals Inc carries a low D/E ratio of 0.40, meaning only $0.40 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 6.45, Elite Pharmaceuticals Inc holds $6.45 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

Elite Pharmaceuticals Inc has a free cash flow margin of 15.3%, earning a moderate score of 46/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Elite Pharmaceuticals Inc earns a strong 45.4% return on equity (ROE), meaning it generates $45 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 72/100. This is up from -8.1% the prior year.

Altman Z-Score Safe

8.35

Elite Pharmaceuticals Inc scores 8.35, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($397.4M) relative to total liabilities ($39.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

6/9

Elite Pharmaceuticals Inc passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

0.53x

For every $1 of reported earnings, Elite Pharmaceuticals Inc generates $0.53 in operating cash flow ($23.7M OCF vs $44.9M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage Safe

441.0x

Elite Pharmaceuticals Inc earns $441.0 in operating income for every $1 of interest expense ($49.1M vs $111K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$148.9M

YoY+77.1%

5Y CAGR+42.4%

10Y CAGR+28.1%

Elite Pharmaceuticals Inc generated $148.9M in revenue in fiscal year 2026. This represents an increase of 77.1% from the prior year.

EBITDA

$50.2M

YoY+141.0%

5Y CAGR+71.1%

Elite Pharmaceuticals Inc's EBITDA was $50.2M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 141.0% from the prior year.

Net Income

$44.9M

YoY+1140.0%

5Y CAGR+54.6%

Elite Pharmaceuticals Inc reported $44.9M in net income in fiscal year 2026. This represents an increase of 1140.0% from the prior year.

EPS (Diluted)

$0.03

Elite Pharmaceuticals Inc earned $0.03 per diluted share (EPS) in fiscal year 2026.

Cash & Balance Sheet

Free Cash Flow

$22.8M

YoY+291.4%

Elite Pharmaceuticals Inc generated $22.8M in free cash flow in fiscal year 2026, representing cash available after capex. This represents an increase of 291.4% from the prior year.

Cash & Debt

$30.3M

YoY+157.2%

5Y CAGR+56.8%

10Y CAGR+10.2%

Elite Pharmaceuticals Inc held $30.3M in cash against $0 in long-term debt as of fiscal year 2026.

Dividends Per Share

N/A

Shares Outstanding

1.08B

YoY+0.8%

5Y CAGR+1.3%

10Y CAGR+4.2%

Elite Pharmaceuticals Inc had 1.08B shares outstanding in fiscal year 2026. This represents an increase of 0.8% from the prior year.

Margins & Returns

Gross Margin

50.4%

YoY+2.7pp

5Y CAGR+3.6pp

10Y CAGR-13.7pp

Elite Pharmaceuticals Inc's gross margin was 50.4% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 2.7 percentage points from the prior year.

Operating Margin

33.0%

YoY+9.7pp

5Y CAGR+24.7pp

10Y CAGR+99.5pp

Elite Pharmaceuticals Inc's operating margin was 33.0% in fiscal year 2026, reflecting core business profitability. This is up 9.7 percentage points from the prior year.

Net Margin

30.1%

YoY+35.3pp

5Y CAGR+10.1pp

10Y CAGR+35.6pp

Elite Pharmaceuticals Inc's net profit margin was 30.1% in fiscal year 2026, showing the share of revenue converted to profit. This is up 35.3 percentage points from the prior year.

Return on Equity

45.4%

YoY+53.4pp

5Y CAGR+13.9pp

Elite Pharmaceuticals Inc's ROE was 45.4% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 53.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$5.7M

YoY-27.9%

5Y CAGR+2.4%

10Y CAGR-7.4%

Elite Pharmaceuticals Inc invested $5.7M in research and development in fiscal year 2026. This represents a decrease of 27.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$926K

YoY-43.0%

Elite Pharmaceuticals Inc invested $926K in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 43.0% from the prior year.

ELTP Income Statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Revenue	$148.9M+77.1%	$84.0M+48.4%	$56.6M+65.8%	$34.2M+5.9%	$32.3M+27.1%	$25.4M
Cost of Revenue	$73.8M+68.0%	$44.0M+45.2%	$30.3M+72.4%	$17.6M+0.5%	$17.5M+29.3%	$13.5M
Gross Profit	$75.0M+87.2%	$40.1M+52.1%	$26.4M+58.8%	$16.6M+12.2%	$14.8M+24.7%	$11.9M
R&D Expenses	$5.7M-27.9%	$8.0M+15.7%	$6.9M+11.0%	$6.2M+53.0%	$4.1M-20.8%	$5.1M
SG&A Expenses	$17.6M+95.5%	$9.0M+26.0%	$7.1M+39.5%	$5.1M+14.7%	$4.5M+34.3%	$3.3M
Operating Income	$49.1M+150.6%	$19.6M+81.7%	$10.8M+193.5%	$3.7M-27.5%	$5.1M+140.9%	$2.1M
Interest Expense	$111K-13.2%	$128K-78.2%	$589K-47.1%	$1.1M+480.1%	$192K-26.1%	$260K
Income Tax	$11.9M+180.2%	$4.3M+121.7%	-$19.6M-4733.1%	$424K+124.4%	-$1.7M	N/A
Net Income	$44.9M+1140.0%	-$4.3M-121.5%	$20.1M+464.6%	$3.6M-60.0%	$8.9M+74.9%	$5.1M
EPS (Diluted)	$0.03	$0.00-100.0%	$0.02	$0.00-100.0%	$0.01	$0.00

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Revenue	$40.7M+29.0%	$31.6M-13.0%	$36.3M-9.7%	$40.2M+25.7%	$32.0M+122.7%	$14.4M-23.9%	$18.9M+0.4%	$18.8M
Cost of Revenue	$20.0M+7.2%	$18.6M-16.2%	$22.2M+71.3%	$13.0M-11.7%	$14.7M+78.3%	$8.2M-22.8%	$10.7M+3.4%	$10.3M
Gross Profit	$20.8M+60.4%	$13.0M-8.0%	$14.1M-48.3%	$27.2M+57.4%	$17.3M+182.6%	$6.1M-25.4%	$8.2M-3.3%	$8.5M
R&D Expenses	$1.6M+57.8%	$1.0M-24.9%	$1.4M-17.3%	$1.7M-18.0%	$2.0M+13.8%	$1.8M-8.8%	$2.0M-9.1%	$2.2M
SG&A Expenses	$7.7M+212.1%	$2.5M-38.8%	$4.0M+18.4%	$3.4M+67.3%	$2.0M-25.3%	$2.7M+19.8%	$2.3M+15.5%	$2.0M
Operating Income	$10.2M+13.0%	$9.0M+9.7%	$8.2M-62.1%	$21.7M+94.6%	$11.2M+916.0%	$1.1M-68.5%	$3.5M-9.8%	$3.9M
Interest Expense	$27K-2.2%	$27K-2.7%	$28K-1.9%	$29K-1.1%	$29K-6.3%	$31K-6.2%	$33K-5.0%	$35K
Income Tax	$2.4M+6.9%	$2.2M+12.7%	$2.0M-62.6%	$5.3M+134.0%	$2.3M+850.8%	$239K-84.2%	$1.5M+554.0%	$232K
Net Income	$18.5M-0.7%	$18.6M+35.7%	$13.7M+332.8%	-$5.9M-134.6%	$17.0M+256.1%	-$10.9M+1.3%	-$11.0M-1892.3%	$616K
EPS (Diluted)	N/A	$0.010.0%	$0.01+200.0%	$-0.01	N/A	$-0.010.0%	$-0.01	$0.00

ELTP Balance Sheet

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Total Assets	$138.3M+43.5%	$96.4M+15.2%	$83.7M+104.6%	$40.9M+16.4%	$35.1M+34.2%	$26.2M
Current Assets	$112.1M+94.2%	$57.7M+44.3%	$40.0M+86.0%	$21.5M+14.0%	$18.9M+54.7%	$12.2M
Cash & Equivalents	$30.3M+157.2%	$11.8M+65.6%	$7.1M-9.3%	$7.8M-8.2%	$8.5M+167.3%	$3.2M
Inventory	$21.3M+30.9%	$16.2M+25.6%	$12.9M+35.4%	$9.6M+41.7%	$6.7M+34.5%	$5.0M
Accounts Receivable	$59.7M+104.5%	$29.2M+50.1%	$19.5M+528.6%	$3.1M+1.2%	$3.1M-12.5%	$3.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$39.4M-8.1%	$42.9M+64.4%	$26.1M+118.4%	$11.9M+20.2%	$9.9M-1.1%	$10.0M
Current Liabilities	$17.4M+46.9%	$11.8M-9.3%	$13.0M+66.6%	$7.8M+17.0%	$6.7M+15.2%	$5.8M
Long-Term Debt	N/A	N/A	N/A	N/A	$1.2M-15.3%	$1.5M
Total Equity	$98.9M+84.8%	$53.5M-7.1%	$57.6M+98.8%	$29.0M+14.8%	$25.2M+56.2%	$16.2M
Retained Earnings	-$75.8M+37.2%	-$120.7M-3.7%	-$116.4M+14.7%	-$136.5M+2.5%	-$140.1M+6.0%	-$149.0M

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Total Assets	$138.3M+9.4%	$126.4M+7.8%	$117.2M+5.3%	$111.3M+15.5%	$96.4M+6.2%	$90.8M+2.9%	$88.2M+0.4%	$87.8M
Current Assets	$112.1M+15.8%	$96.8M+12.8%	$85.8M+10.2%	$77.9M+34.8%	$57.7M+20.2%	$48.0M+6.1%	$45.3M+4.9%	$43.2M
Cash & Equivalents	$30.3M+40.4%	$21.6M-20.4%	$27.1M+22.0%	$22.2M+88.6%	$11.8M+34.6%	$8.7M-12.6%	$10.0M+13.0%	$8.8M
Inventory	$21.3M-15.3%	$25.1M+38.2%	$18.2M-6.2%	$19.4M+19.2%	$16.2M-19.4%	$20.2M+42.3%	$14.2M+2.4%	$13.8M
Accounts Receivable	$59.7M+23.1%	$48.5M+18.7%	$40.9M+12.8%	$36.2M+24.0%	$29.2M+58.3%	$18.5M-13.9%	$21.4M+4.7%	$20.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$39.4M-14.5%	$46.1M-17.2%	$55.7M-12.6%	$63.7M+48.5%	$42.9M-21.1%	$54.3M+32.7%	$40.9M+38.3%	$29.6M
Current Liabilities	$17.4M+31.9%	$13.2M+23.6%	$10.7M-0.8%	$10.8M-9.1%	$11.8M-19.4%	$14.7M+14.3%	$12.9M-8.3%	$14.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$98.9M+23.1%	$80.3M+30.4%	$61.6M+29.2%	$47.7M-10.9%	$53.5M+46.8%	$36.4M-22.9%	$47.3M-18.9%	$58.3M
Retained Earnings	-$75.8M+19.6%	-$94.3M+16.5%	-$112.9M+10.8%	-$126.6M-4.9%	-$120.7M+12.3%	-$137.7M-8.6%	-$126.8M-9.5%	-$115.8M

ELTP Cash Flow Statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	$23.7M+218.5%	$7.5M+330.5%	-$3.2M-196.9%	$3.3M-48.7%	$6.5M+103.8%	$3.2M
Capital Expenditures	$926K-43.0%	$1.6M+100.7%	$810K-85.9%	$5.7M+1050.6%	$499K	N/A
Free Cash Flow	$22.8M+291.4%	$5.8M+244.2%	-$4.0M-68.7%	-$2.4M-139.9%	$6.0M	N/A
Investing Cash Flow	-$926K+61.4%	-$2.4M-196.4%	-$810K+85.9%	-$5.7M-1050.6%	-$499K-89.7%	-$263K
Financing Cash Flow	-$4.3M-423.4%	-$826K-124.7%	$3.3M+96.2%	$1.7M+355.2%	-$667K+23.3%	-$870K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Operating Cash Flow	$9.1M+273.3%	-$5.3M-203.4%	$5.1M-65.5%	$14.8M+277.1%	$3.9M+468.3%	-$1.1M-173.0%	$1.5M-53.7%	$3.1M
Capital Expenditures	$398K+93.1%	$206K+99.4%	$103K-52.6%	$218K-71.1%	$754K	$0-100.0%	$92K-88.1%	$779K
Free Cash Flow	$8.7M+259.5%	-$5.5M-209.7%	$5.0M-65.6%	$14.6M+360.1%	$3.2M+397.4%	-$1.1M-178.0%	$1.4M-42.3%	$2.4M
Investing Cash Flow	-$398K-93.1%	-$206K-99.4%	-$103K+52.6%	-$218K+71.1%	-$754K	$0-100.0%	$18K+101.1%	-$1.7M
Financing Cash Flow	-$42K-23.4%	-$34K+71.1%	-$116K+97.2%	-$4.1M-2914.1%	-$137K+29.0%	-$193K+39.8%	-$321K-83.3%	-$175K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ELTP Financial Ratios

Metric	FY26	FY25	FY24	FY23	FY22	FY21
Gross Margin	50.4%+2.7pp	47.7%+1.1pp	46.6%-2.0pp	48.6%+2.7pp	45.9%-0.9pp	46.8%
Operating Margin	33.0%+9.7pp	23.3%+4.3pp	19.1%+8.3pp	10.8%-5.0pp	15.7%+7.4pp	8.3%
Net Margin	30.1%+35.3pp	-5.1%-40.6pp	35.5%+25.1pp	10.4%-17.1pp	27.6%+7.5pp	20.1%
Return on Equity	45.4%+53.4pp	-8.1%-43.0pp	34.9%+22.6pp	12.3%-23.0pp	35.3%+3.8pp	31.5%
Return on Assets	32.5%+36.9pp	-4.5%-28.5pp	24.0%+15.3pp	8.7%-16.6pp	25.3%+5.9pp	19.4%
Current Ratio	6.45+1.6	4.88+1.8	3.07+0.3	2.75-0.1	2.82+0.7	2.10
Debt-to-Equity	0.40-0.4	0.80+0.3	0.45+0.0	0.41+0.4	0.05-0.0	0.09
FCF Margin	15.3%+8.4pp	6.9%+14.1pp	-7.1%-0.1pp	-7.0%-25.7pp	18.6%	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Gross Margin	51.0%+10.0pp	41.0%+2.3pp	38.8%-29.0pp	67.7%+13.7pp	54.0%+11.4pp	42.6%-0.8pp	43.4%-1.7pp	45.1%
Operating Margin	25.0%-3.5pp	28.5%+5.9pp	22.6%-31.4pp	54.0%+19.1pp	34.9%+27.2pp	7.6%-10.8pp	18.5%-2.1pp	20.5%
Net Margin	45.3%-13.6pp	58.9%+21.1pp	37.7%+52.4pp	-14.6%-67.8pp	53.1%+128.9pp	-75.8%-17.4pp	-58.5%-61.7pp	3.3%
Return on Equity	18.7%-4.5pp	23.2%+0.9pp	22.3%+34.6pp	-12.3%-44.1pp	31.8%+61.7pp	-29.9%-6.5pp	-23.4%-24.4pp	1.1%
Return on Assets	13.4%-1.4pp	14.7%+3.0pp	11.7%+17.0pp	-5.3%-22.9pp	17.6%+29.6pp	-12.0%+0.5pp	-12.5%-13.2pp	0.7%
Current Ratio	6.45-0.9	7.34-0.7	8.04+0.8	7.23+2.4	4.88+1.6	3.27-0.3	3.52+0.4	3.08
Debt-to-Equity	0.40-0.2	0.57-0.3	0.90-0.4	1.33+0.5	0.80-0.7	1.49+0.6	0.87+0.4	0.51
FCF Margin	21.5%+38.8pp	-17.4%-31.1pp	13.8%-22.4pp	36.2%+26.3pp	9.9%+17.3pp	-7.4%-14.6pp	7.2%-5.3pp	12.6%

Similar Companies

Nika Pharmaceuticals NIKA

$806.3M

Glass House Brands Inc GLASF

$964.0M

Verano Hldgs VRNOF

$457.2M

Endo Inc NDOI

$1.8B

Cresco Labs CRLBF

$285.8M

Frequently Asked Questions

What is Elite Pharmaceuticals Inc's annual revenue?

Elite Pharmaceuticals Inc (ELTP) reported $148.9M in total revenue for fiscal year 2026. This represents a 77.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Elite Pharmaceuticals Inc's revenue growing?

Elite Pharmaceuticals Inc (ELTP) revenue grew by 77.1% year-over-year, from $84.0M to $148.9M in fiscal year 2026.

Is Elite Pharmaceuticals Inc profitable?

Yes, Elite Pharmaceuticals Inc (ELTP) reported a net income of $44.9M in fiscal year 2026, with a net profit margin of 30.1%.

What is Elite Pharmaceuticals Inc's EBITDA?

Elite Pharmaceuticals Inc (ELTP) had EBITDA of $50.2M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Elite Pharmaceuticals Inc's gross margin?

Elite Pharmaceuticals Inc (ELTP) had a gross margin of 50.4% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Elite Pharmaceuticals Inc's operating margin?

Elite Pharmaceuticals Inc (ELTP) had an operating margin of 33.0% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Elite Pharmaceuticals Inc's net profit margin?

Elite Pharmaceuticals Inc (ELTP) had a net profit margin of 30.1% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Elite Pharmaceuticals Inc's return on equity (ROE)?

Elite Pharmaceuticals Inc (ELTP) has a return on equity of 45.4% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Elite Pharmaceuticals Inc's free cash flow?

Elite Pharmaceuticals Inc (ELTP) generated $22.8M in free cash flow during fiscal year 2026. This represents a 291.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Elite Pharmaceuticals Inc's operating cash flow?

Elite Pharmaceuticals Inc (ELTP) generated $23.7M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Elite Pharmaceuticals Inc's total assets?

Elite Pharmaceuticals Inc (ELTP) had $138.3M in total assets as of fiscal year 2026, including both current and long-term assets.

What are Elite Pharmaceuticals Inc's capital expenditures?

Elite Pharmaceuticals Inc (ELTP) invested $926K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Elite Pharmaceuticals Inc spend on research and development?

Elite Pharmaceuticals Inc (ELTP) invested $5.7M in research and development during fiscal year 2026.

How many shares does Elite Pharmaceuticals Inc have outstanding?

Elite Pharmaceuticals Inc (ELTP) had 1.08B shares outstanding as of fiscal year 2026.

What is Elite Pharmaceuticals Inc's current ratio?

Elite Pharmaceuticals Inc (ELTP) had a current ratio of 6.45 as of fiscal year 2026, which is generally considered healthy.

What is Elite Pharmaceuticals Inc's debt-to-equity ratio?

Elite Pharmaceuticals Inc (ELTP) had a debt-to-equity ratio of 0.40 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Elite Pharmaceuticals Inc's return on assets (ROA)?

Elite Pharmaceuticals Inc (ELTP) had a return on assets of 32.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Elite Pharmaceuticals Inc's Altman Z-Score?

Elite Pharmaceuticals Inc (ELTP) has an Altman Z-Score of 8.35, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Elite Pharmaceuticals Inc's Piotroski F-Score?

Elite Pharmaceuticals Inc (ELTP) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Elite Pharmaceuticals Inc's earnings high quality?

Elite Pharmaceuticals Inc (ELTP) has an earnings quality ratio of 0.53x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Elite Pharmaceuticals Inc cover its interest payments?

Elite Pharmaceuticals Inc (ELTP) has an interest coverage ratio of 441.0x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Elite Pharmaceuticals Inc?

Elite Pharmaceuticals Inc (ELTP) scores 82 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.